$6.47+0.00 (+0.00%)
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.
Related stocks: AAPL · MSFT · NVDA · JPM · XOM